Quantcast
Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to Dividend.com. Please help us personalize your experience.

Select the one that best describes you
Dividend logo

The major pharmaceutical companies are facing quite a predicament. Billions of dollars worth of patent-protected drugs have already gone or are preparing to go generic over the next few years. Dubbed the “patent cliff”, the loss of these blockbusters and other major money-making drugs for the largest pharmaceutical companies is enough to make any investor cringe. For dividend investors, it’s especially troublesome as some of these drugs have been the driving force behind Big Pharma’s status as dividend safe havens.

Rather than resignedly driving over the cliff, Big Pharma has at least begun to pump the brakes and look for alternatives. As a result, Big Pharma has found itself diving head first into biotech manufacturers and their lucrative cures for rare diseases.

Except, it turns out that biotech may not be the panacea they hoped for. Regulation and public scorn could crimp the ability of the biotechs – and correspondingly Big Pharma – to charge an arm and a leg for the medications.

To read the Full Story, Go Premium or Log In

Popular Articles

Premium Shutterstock 412610572
News

The Market Wrap for January 19: Investors Pay No Attention to Possible Government Shutdown

Despite the possibility that the U.S. Federal Government is once again going to shut down on...

News

Trending: Ford Says Goodbye to Mass-Market Cars

Dividend.com analyzes the search patterns of our visitors each week. By sharing these trends with...

Dividend Investing Ideas Center

In Spite of the 90% Rule, Why Do Some REITs Have Poor Payout Ratios?

Real estate investment trusts (REITs) have grown in popularity since the financial crisis, so...